There were documented significant instances of peliosis hepatis, at times linked to liver failure and intra-abdominal hemorrhage; liver tumors, occasionally deadly; and blood lipid changes associated with greater possibility of atherosclerosis led FDA to get rid of acceptance in June 2023. Supplemental warnings consist of the pitfalls linked to cho